Andrew Moultrie
A5028244399- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Vaccine Coverage and Hesitancy
- Respiratory viral infections research
- Pneumonia and Respiratory Infections
- Immunodeficiency and Autoimmune Disorders
- Virology and Viral Diseases
- Immune responses and vaccinations
- Influenza Virus Research Studies
- Neonatal and Maternal Infections
- COVID-19 epidemiological studies
- SARS-CoV-2 detection and testing
- Viral gastroenteritis research and epidemiology
- Maternal and Neonatal Healthcare
- Global Maternal and Child Health
- Syphilis Diagnosis and Treatment
- Streptococcal Infections and Treatments
- Hepatitis Viruses Studies and Epidemiology
- Long-Term Effects of COVID-19
- Parvovirus B19 Infection Studies
- Hepatitis C virus research
- COVID-19 and Mental Health
- Congenital Diaphragmatic Hernia Studies
- Bacterial Infections and Vaccines
- Rabies epidemiology and control
University of the Witwatersrand
2019-2023
South African Medical Research Council
2020-2023
National Research Foundation
2019-2022
University of Oxford
2021
AstraZeneca (Brazil)
2021
National Health Laboratory Service
2021
Respiratory and Meningeal Pathogens Research Unit
2019-2020
University of London
2020
Guy's and St Thomas' NHS Foundation Trust
2020
St Thomas' Hospital
2020
Assessment of the safety and efficacy vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in different populations is essential, as investigation emerging SARS-CoV-2 variants concern, including B.1.351 (501Y.V2) variant first identified South Africa.
People living with HIV are at an increased risk of fatal outcome when admitted to hospital for severe COVID-19 compared HIV-negative individuals. We aimed assess safety and immunogenicity the ChAdOx1 nCoV-19 (AZD1222) vaccine in people individuals South Africa.
Abstract Background Assessing safety and efficacy of Covid-19 vaccines in different populations is essential, as investigation against emerging SARS-CoV-2 variants concern including the B.1.351 (501Y.V2) variant first identified South Africa. Methods We conducted a randomized multicentre, double blinded controlled trial on ChAdOx1-nCoV19 HIV-uninfected people Participants age 18 to <65 years (1:1) two doses vaccine containing 5×10 10 viral particles or placebo (0.9%NaCl) 21-35 days apart....
Abstract Background Limitations in laboratory testing capacity undermine the ability to quantify overall burden of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. Methods We undertook a population-based serosurvey for SARS-CoV-2 infection 26 subdistricts, Gauteng Province (population 15.9 million), South Africa, estimate infection, fatality rate (IFR) triangulating seroprevalence, recorded COVID-19 deaths and excess-mortality data. employed three-stage random...
Abstract Background Lower respiratory tract infections are a leading cause of death in young children, but few studies have collected the specimens needed to define role specific causes. The Child Health and Mortality Prevention Surveillance (CHAMPS) platform aims investigate causes children aged &lt;5 years high–mortality rate settings, using postmortem minimally invasive tissue sampling other advanced diagnostic techniques. We examined findings for deaths identified CHAMPS sites 7...
Abstract From April to September 2020, we investigated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in a cohort of 396 healthcare workers (HCWs) from 5 departments at Chris Hani Baragwanath Hospital, South Africa. Overall, 34.6% HCWs had polymerase chain reaction–confirmed SARS-CoV-2 infection (132.1 [95% confidence interval, 111.8–156.2] per 1000 person-months); an additional 27 were identified by serology. the internal medicine department highest rate (61.7%)....
Pneumococcal conjugate vaccine (PCV) immunisation has reduced vaccine-serotype colonisation and invasive pneumococcal disease in South Africa, providing the opportunity to consider transitioning from a two-dose (2 + 1) one-dose (1 primary series booster dose.In this single-centre, open-label, randomised trial done infants aged 35-49 days without HIV infection, childhood immunisations except for BCG polio, with gestation age at delivery of least 37 weeks age, birthweight 2500 g, weight 3500 g...
Invasive Group B Streptococcus (GBS) is a common cause of early-onset neonatal sepsis and also associated with stillbirth. This study aimed to determine the proportion stillborn infants who died between 0 90 days attributable GBS using postmortem minimally invasive tissue sampling (MITS) in 7 low- middle-income countries (LMICs) participating Child Health Mortality Prevention Surveillance (CHAMPS). Deaths that occurred December 2016 2021 were investigated MITS, including culture for bacteria...
BackgroundStandard-dose, seasonal, trivalent, inactivated influenza vaccine induces moderate-to-low haemagglutination-inhibition antibody responses in people living with HIV. This study assessed the immunogenicity and safety of different dosing schedules pregnant women HIV South Africa.MethodsIn this double-blind, randomised, controlled trial, we recruited from seven antenatal clinics Soweto, Africa. Pregnant were eligible if they aged 18–38 years, infected HIV, had an estimated gestational...
Licensure of a group B Streptococcus (GBS) polysaccharide-protein conjugate vaccine for protecting infants against invasive GBS disease (IGbsD) will likely need to be based on demonstrating safety in pregnant women, and benchmarking immunogenicity serological threshold associated with risk reduction IGbsD. We investigated the association between naturally derived serotype Ia III IgG IGbsD ≤90 days age.In matched case-control study, cases were identified from cohort 38 233 mother-newborn...
Abstract Coronavirus disease 2019 (COVID-19) is a public health emergency of international concern 1 . People living with HIV (PLWH) are at increased risk for adverse COVID-19 outcomes compared HIV-negative individuals 2-5 , and high-risk group prevention 4 The ChAdOx1 nCoV-19 (AZD1222) vaccine has demonstrated safety efficacy against in clinical trials 6-8 To date, there no reports on the immunogenicity this, or any vaccine, PLWH, vaccines Africa limited 9 Here, we show comparable two doses...
Measles morbidity and mortality rates are greatest in children <12 months old, with increased susceptibility human immunodeficiency virus (HIV)-exposed children. We evaluated the immunogenicity safety of an early 2-dose measles vaccine regimen administered at 6 12 age South Africa.HIV-unexposed (HU) (n = 212) HIV-exposed, uninfected (HEU) 71) received vaccination (CAM-70) age. immunoglobulin G titers were measured by means enzyme-linked immunosorbent assay before 1 month after each dose.The...
Measles infection causes particularly severe disease in young children who, prior to vaccination, are dependent on maternal antibodies for protection against infection. vaccination was introduced into the South African public immunization programme 1983 and became widely available 1992. The aim of this study determine measles-specific immunoglobulin G (IgG) levels pregnant women living with without HIV born before after measles vaccine introduction Africa.Measles IgG antibody level from...
Rubella infection during pregnancy may cause foetal death or congenital rubella syndrome. In South Africa, the national public immunization programme does not include vaccination. The aim of this study was to evaluate sero-epidemiology in pregnant African women living with and without HIV.Serum samples obtained from HIV (n=552) were tested for immunoglobulin G antibodies using an ELISA. proportions seronegative titres (<8IU/ml) seropositive (≥11IU/ml), geometric mean (GMT) compared by age...
Background: Limitations in laboratory testing capacity undermine the ability to quantify overall burden of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection. We undertook a cross-sectional population based sero-survey for SARS-CoV-2 infection 26 sub-districts, Gauteng Province (population 15·9 million), South Africa. Furthermore, we estimated mortality risk triangulating seroprevalence, recorded COVID-19 deaths and excess data.Methods: employed multi-stage random...
Transplacental hMPV-neutralizing antibody transfer was reduced from mothers living with HIV-1. However, a comparison of titers at birth between hMPV hospitalization cases <6 months and matched controls suggested that maternal might not be the primary cause previously reported elevated risk in HIV-1-exposed infants.